Elixir Medical Corporation Announces Outstanding 5-Year Clinical Data for CE Mark-Approved DESolve Novolimus Eluting Bioresorbable Coronary Scaffold System

Excellent Six-Month Safety and Efficacy Results for Next-Generation Thin-strut DESolveĀ®Ā Cx Novolimus Eluting Bioresorbable Coronary Scaffold System also presented Milpitas, CAĀ ā€“Ā May 17, 2017Ā ā€” Elixir Medical Corporation, a developer of products that combine state-of-the-art medical devices with advanced pharmaceuticals, today announced excellent 5-year clinical data from the DESolve Nx international pivotal clinical trial for the CE Mark-approved, […]